SK612000A3 - Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition - Google Patents

Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition Download PDF

Info

Publication number
SK612000A3
SK612000A3 SK61-2000A SK612000A SK612000A3 SK 612000 A3 SK612000 A3 SK 612000A3 SK 612000 A SK612000 A SK 612000A SK 612000 A3 SK612000 A3 SK 612000A3
Authority
SK
Slovakia
Prior art keywords
compound
insulin
pharmaceutical composition
diabetes mellitus
comprises administering
Prior art date
Application number
SK61-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SK612000A3 publication Critical patent/SK612000A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
SK61-2000A 1997-07-18 1998-07-16 Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition SK612000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002112 WO1999003478A1 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Publications (1)

Publication Number Publication Date
SK612000A3 true SK612000A3 (en) 2000-07-11

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
SK61-2000A SK612000A3 (en) 1997-07-18 1998-07-16 Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition

Country Status (27)

Country Link
EP (1) EP1001784A1 (es)
JP (1) JP2001510160A (es)
KR (1) KR20010021952A (es)
CN (1) CN1263467A (es)
AP (1) AP2000001735A0 (es)
AR (2) AR016350A1 (es)
AU (1) AU8449098A (es)
BG (1) BG104062A (es)
BR (1) BR9810292A (es)
CA (1) CA2297133A1 (es)
CO (1) CO4940489A1 (es)
DZ (1) DZ2563A1 (es)
EA (1) EA200000140A1 (es)
GB (1) GB9715298D0 (es)
HU (1) HUP0003626A3 (es)
ID (1) ID23804A (es)
IL (1) IL133907A0 (es)
MA (1) MA24608A1 (es)
NO (1) NO20000230L (es)
OA (1) OA11312A (es)
PE (1) PE99499A1 (es)
PL (1) PL338140A1 (es)
SK (1) SK612000A3 (es)
TR (1) TR200000133T2 (es)
UY (1) UY25101A1 (es)
WO (1) WO1999003478A1 (es)
ZA (1) ZA986364B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DK1133312T3 (da) 1999-06-21 2008-01-02 Lilly Co Eli Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes
ES2301142T3 (es) * 2000-01-21 2008-06-16 Novartis Ag Combinaciones que comprenden inhibidores de dipeptidilpeptidasa-iv y agentes antidiabeticos.
EP1295609A4 (en) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd DRUGS CONTAINING COMBINED ACTIVE INGREDIENTS
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0601001T3 (da) * 1991-08-26 1997-10-20 Upjohn Co Flydende næringsmiddelprodukt indeholdende 3-guanidinopropionsyre.
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
OA11312A (en) 2003-10-24
MA24608A1 (fr) 1999-04-01
CO4940489A1 (es) 2000-07-24
HUP0003626A2 (hu) 2001-05-28
ZA986364B (en) 2000-01-17
AP2000001735A0 (en) 2000-01-16
AR016350A1 (es) 2001-07-04
CA2297133A1 (en) 1999-01-28
PL338140A1 (en) 2000-09-25
CN1263467A (zh) 2000-08-16
GB9715298D0 (en) 1997-09-24
IL133907A0 (en) 2001-04-30
KR20010021952A (ko) 2001-03-15
DZ2563A1 (fr) 2003-02-15
WO1999003478A1 (en) 1999-01-28
NO20000230D0 (no) 2000-01-17
EP1001784A1 (en) 2000-05-24
PE99499A1 (es) 1999-12-18
BG104062A (en) 2000-11-30
TR200000133T2 (tr) 2000-09-21
HUP0003626A3 (en) 2001-12-28
JP2001510160A (ja) 2001-07-31
EA200000140A1 (ru) 2000-06-26
BR9810292A (pt) 2000-09-19
AU8449098A (en) 1999-02-10
UY25101A1 (es) 2000-12-29
AR019724A2 (es) 2002-03-13
ID23804A (id) 2000-05-11
NO20000230L (no) 2000-01-17

Similar Documents

Publication Publication Date Title
SK179299A3 (en) Use of insulin sensitiser and a biguanide antihyperglycaemic agent
JP2005213273A (ja) チアゾリジンジオン、インスリン分泌促進薬およびジグアニドを用いる糖尿病の治療
US20080058388A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
JP2005247865A (ja) チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
SK179399A3 (en) Use of insulin sensitiser and an insulin
SK612000A3 (en) Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition
SK179199A3 (en) The use of an insulin sensitiser and an insulin secretagogue promoter
SK179499A3 (en) The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
US20040122060A1 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20020045649A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
US20030092750A1 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
KR20010024482A (ko) 고혈당증 치료용 티아졸리딘디온의 용도
MXPA00000633A (es) Composición farmacéutica con tiazolidinodiona, secretagogo de insulina y biguanida para el tratamiento de diabetes mellitus
MXPA00000631A (es) Tratamiento de diabetes con tiazolidinodiona y sulfonilurea
MXPA00000655A (es) Tratamiento de diabetes con tiazolidinodiona, secretagogo de insulina e inhibidor de alfa-glucosidasa
CZ2000172A3 (cs) Léčivo pro léčbu diabetes mellitus a stavů s diabetes mellitus spojených a farmaceutický prostředek